Acrivon Therapeutics (ACRV): Prakiraan wutah bathi saben saham kanggo taun ngarep

Logo perusahaan publik Acrivon (ACRV)

Acrivon Therapeutics (ACRV) EPS projections for next year, with the metric at 13.80, highlight the potential of precision proteomics and the development of CHK1/2 inhibitors. Growth is driven by AI-powered synthesis automation, although clinical trials remain under physician supervision. Laboratories in Massachusetts and the engagement of external CDMO facilities ensure process stability and eliminate operational downtime.

Acrivon Pharma (ACRV): Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep saka 28.04.2023 nganti 15.11.2026

Rincian metrik lan analitis perusahaan Acrivon Therapeutics Inc (ACRV)

- rega lan prakiraan konsensus rega:
Bagan rega Acrivon Therapeutics Inc|ACRV - Rata-rata rega prakiraan
- data kapitalisasi bursa:
Biji pasar Acrivon Therapeutics, Inc.|ACRV - Nilai Perusahaan
- informasi kapitalisasi buku:
Aset Bersih saben Siji Saham Acrivon Therapeutics|ACRV - Pambiji Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih acrivon.com|ACRV - Nilai Agregat Aset
- rincian utang lan likuiditas:
Utang marang Ekuitas Acrivon Therapeutics|ACRV - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Acrivon Therapeutics|ACRV - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku Acrivon|ACRV - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Acrivon Therapeutics|Likuiditas cepet acrivon.com
- data bathi resik lan rasio valuasi:
ACRV - Bathi resik perusahaan|Bathi sing dikarepake Acrivon Therapeutics|ACRV - Kapitalisasi marang bathi|Pangali Forward P/E acrivon.com|ACRV - Rasio rega marang wutah bathi resik|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Acrivon Therapeutics|ACRV - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Acrivon Therapeutics|ACRV - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan acrivon.com|ACRV - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Acrivon Therapeutics
- rincian pendapatan lan dodolan:
ACRV - Pendapatan dodolan perusahaan|Prakiraan volume dodolan acrivon.com|ACRV - Koefisien rega marang pendapatan|Multiplikator forward rega marang pendapatan Acrivon Therapeutics Inc|ACRV - Wutah dodolan YoY sajrone rolas wulan kepungkur
Analisis umum perusahaan:acrivon.com, ACRV
Barang utama Acrivon Therapeutics, Inc.

The AP3T precision oncology platform ensures high clinic adherence to Acrivon Therapeutics (ACRV) protocols, establishing a foundation for revenue scaling. The trend in consensus earnings per share (EPS) estimates reflects the expected trajectory of adjusted net income, directly determining the fair P/E multiple. Growth in this metric signals a business valuation rerating, allowing investors to avoid capital losses in overvalued assets.

Analisis perusahaan pesaing

Prakiraan wutah bathi resik saben saham kanggo taun ngarep NovoCure Ltd|Prakiraan wutah bathi resik saben saham ing taun ngarep Alpha Tau Medical DRTS|Prakiraan wutah bathi saben saham kanggo taun ngarep FBIO (fortressbiotech.com)|Prakiraan wutah bathi kanggo taun ngarep Allarity Therapeutics Inc. (ALLR)